Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods of treating fragile X associated disorders, ADHD, and autism spectrum disorder

a technology of adhd and autism spectrum disorder, applied in the direction of anhydride/acid/halide active ingredients, drug compositions, tetracycline active ingredients, etc., can solve the problems of early cessation, high and increased risk of abuse of stimulants

Active Publication Date: 2017-12-12
OTSUKA AMERICA PHARMA INC
View PDF21 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Affected women may exhibit intermittent and unpredictable menses, with eventual early cessation.
However, concerns about stimulants include risk of abuse, dependency, and diversion as well as potential neurotoxic effects of amphetamines.
It has been reported, however, that some individuals with FXS failed treatment predominately due to aggravation of aggressive, perseverative, and irritable behavior.
Six trials of atomoxetine in individuals with FXS, however, were unsuccessful, with the majority failing due to aggravation of irritable, moody, and aggressive behaviors.
However, as discussed above, concerns about treatment with stimulants include risk of abuse, dependency, and diversion as well as potential neurotoxic effects of amphetamines.
In addition, stimulants may exacerbate anxiety.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of treating fragile X associated disorders, ADHD, and autism spectrum disorder

Examples

Experimental program
Comparison scheme
Effect test

example

Example 1

[0325]Sustained release pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride

[0326]

Tablet UnitConcentrationWeightIngredient(% W / W)(mg)(1R,5S)-1-(naphthalen-2- 25%100yl)-3-azabicyclo[3.1.0]hexanehydrochlorideLactose, Monohydrate,74.5% 298NFHypromellose, NF(as 50 / 50 premix -RetaLac ®)Magnesium Stearate, NF 0.5%2(Hyqual ® Vegetablesource)Total100%400

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
spectrum disorderaaaaaaaaaa
fragileaaaaaaaaaa
weight/weightaaaaaaaaaa
Login to View More

Abstract

Provided are novel methods comprising administering a therapeutically effective amount of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, to a patient in need thereof.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application is the National Stage Entry under 35 U.S.C. §371 of International Application No. PCT / US2014 / 069401 filed Dec. 9, 2014, which claims priority to U.S. Provisional Application No. 61 / 913,886 filed Dec. 9, 2013, the contents of both of which are hereby incorporated by reference.BACKGROUND[0002]Fragile X-associated disorders are a family of genetic conditions that may affect individuals in a variety of ways. The three fragile X-associated disorders are fragile X syndrome (FXS), fragile X-associated tremor / ataxia syndrome (FXTAS), and fragile X-associated primary ovarian insufficiency (FXPOI). The conditions are all caused by changes in the fragile X mental retardation 1 (FMR1) gene, located on the X chromosome. In most people, the FMR1 gene contains approximately 5-44 repeats of the cytosine guanine guanine (CGG) trinucleotide within the 5′ untranslated region.[0003]Fragile X syndrome (FXS) is the most common inherited form o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): A61K31/403A61K31/185A61K31/27A61K31/65A61K9/20A61K45/06
CPCA61K31/403A61K9/2013A61K45/06A61K31/65A61K31/27A61K31/185A61K9/2054A61K9/2018A61K2300/00A61P25/28A61P25/30A61P43/00
Inventor MCKINNEY, ANTHONYGENTILE, FRANKHSU, TIMOTHYBYMASTER, FRANKLINPISKORSKI, WALTERWELTER, RICHARD
Owner OTSUKA AMERICA PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products